Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
ncbi.nlm.nih.gov/pmc/articles/PMC3206257 Sikiric P, et al
Research Findings The research history of AOD9604 spans multiple phases of preclinical and clinical development, with generally positive findings regarding efficacy for body fat reduction and favorable safety compared to growth hormone, though ultimate regulatory approval has remained elusive
The usual course of treatment is 4 sessions over 4 to 6 weeks, with monthly maintenance
Rapid intravenous infusion can precipitate hypotension, while electrolyte disturbances may occur with inappropriate dosing or prolonged use
US$ 25.34
US$ 24.94
US$ 28.07
US$ 27.81
US$ 28.48
